Our cancer immunotherapy franchise is focused on developing therapeutics based on Natural Killer (NK) cells.
NK cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK-cells not only detect and identify malignant cancer cells, but they also induce cancer cell death and even help trigger a broader adaptive immune response.1
Kiadis’ NK-cell program consists of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors. Our proprietary off-the-shelf NK-cell platform is based on NK-cells from a unique universal donor, expanded and activated ex vivo using our PM21 particle technology. The Kiadis off-the-shelf platform has the potential to make NK-cell therapy products rapidly and economically available for a broad patient population across a potentially wide range of indications.
The K-NK pipeline includes:
K-NK002: A phase 1/2 evaluating haplo-identical NK cells to prevent post-transplant relapse in AML and MDS. This study was designed based on clinical proof-of-concept data from MD Anderson Cancer Center showing a Complete Remission (CR) rate of 69% in contrast to historical CR rates of 20-26%.2 K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical Trial Network (BMT CTN), which consists of the premier transplant centers in the United States.3
K-NK003: A phase 1 study will begin in 2020 evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML).
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid cancers.
1. Chiossone L, et al, Natural killer cells and other innate lymphoid cells in cancer. Nat Reviews 18; 671-688 (2018)
2. Ciurea SO, et al, ASCO Presentation June 2, 2018